Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High Folate Receptor-Alpha Expression”

9 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 9 of 9 results

Large-scale testing (Phase 3)Study completedNCT04209855
What this trial is testing

Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

Who this might be right for
Epithelial Ovarian CancerPeritoneal CancerFallopian Tube Cancer
AbbVie 453
Large-scale testing (Phase 3)Looking for participantsNCT05445778
What this trial is testing

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Who this might be right for
Ovarian CancerPeritoneal CancerFallopian Tube Cancer
AbbVie 520
Large-scale testing (Phase 3)Study completedNCT04296890
What this trial is testing

Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

Who this might be right for
Epithelial Ovarian CancerPeritoneal CancerFallopian Tube Cancer
ImmunoGen, Inc. 106
Large-scale testing (Phase 3)UnknownNCT05622890
What this trial is testing

A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer

Who this might be right for
Epithelial Ovarian CancerPeritoneal CancerFallopian Tube Cancer
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 35
Testing effectiveness (Phase 2)Looking for participantsNCT06682988
What this trial is testing

Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

Who this might be right for
Advanced High-Grade Epithelial OvarianPrimary PeritonealFallopian Tube Cancers+2 more
AbbVie 110
Testing effectiveness (Phase 2)Ended earlyNCT05001282
What this trial is testing

Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Who this might be right for
Ovarian CancerOvarian NeoplasmsOvarian Carcinoma+22 more
Elucida Oncology 79
Testing effectiveness (Phase 2)Study completedNCT05041257
What this trial is testing

Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers

Who this might be right for
Ovarian CancerPeritoneal CancerFallopian Tube Cancer
AbbVie 79
Testing effectiveness (Phase 2)Active Not RecruitingNCT05456685
What this trial is testing

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Who this might be right for
High Grade Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
AbbVie 125
Testing effectiveness (Phase 2)Looking for participantsNCT06365853
What this trial is testing

Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

Who this might be right for
Recurrent Ovarian CancerFolate Receptor-Alpha Positive
AbbVie 100